PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 63.9443

Change

0.00 (0.00)%

Market Cap

N/A

Volume

2.70K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-15 )

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.89% 33% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.89% 33% F 30% F
Trailing 12 Months  
Capital Gain 0.19% 62% D 43% F
Dividend Return 0.01% 7% C- N/A F
Total Return 0.20% 62% D 33% F
Trailing 5 Years  
Capital Gain 15.03% 43% F 45% F
Dividend Return 0.08% 5% F N/A F
Total Return 15.11% 43% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain 1.23% 52% F 44% F
Dividend Return 1.25% 52% F 32% F
Total Return 0.02% 11% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 15.83% 57% F 59% D-
Risk Adjusted Return 7.90% 48% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.